Lacosamide
Phase 3Completed 0 watching 0 views this week๐ Rising
74
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Epilepsy With Partial-onset Seizures
Conditions
Epilepsy With Partial-onset Seizures
Trial Timeline
Jun 5, 2015 โ May 28, 2020
NCT ID
NCT02477839About Lacosamide
Lacosamide is a phase 3 stage product being developed by UCB for Epilepsy With Partial-onset Seizures. The current trial status is completed. This product is registered under clinical trial identifier NCT02477839. Target conditions include Epilepsy With Partial-onset Seizures.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03559673 | Pre-clinical | Completed |
| NCT04627285 | Phase 3 | Completed |
| NCT02710890 | Phase 2/3 | Completed |
| NCT02582866 | Phase 3 | Completed |
| NCT02477839 | Phase 3 | Completed |
| NCT02124564 | Phase 3 | Completed |
| NCT01969851 | Phase 2 | Completed |
| NCT01921205 | Phase 3 | Completed |
| NCT01724918 | Phase 2 | Terminated |
| NCT01832038 | Phase 3 | Completed |
| NCT01673282 | Pre-clinical | Completed |
| NCT01530386 | Phase 1 | Completed |
| NCT01484977 | Phase 3 | Completed |
| NCT01236001 | Pre-clinical | Completed |
| NCT01118962 | Phase 2 | Completed |
| NCT01235403 | Approved | Completed |
| NCT01118949 | Phase 2 | Completed |
| NCT00938431 | Phase 2 | Completed |
| NCT00955357 | Approved | Completed |
| NCT00771927 | Pre-clinical | Completed |
Competing Products
20 competing products in Epilepsy With Partial-onset Seizures
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| perampanel | Eisai | Phase 2 | 52 |
| Lacosamide | UCB | Phase 3 | 74 |
| Zonisamide + Placebo | Eisai | Phase 3 | 77 |
| Zonegran | Eisai | Approved | 85 |
| perampanel + perampanel | Eisai | Phase 1 | 33 |
| Perampanel + Placebo | Eisai | Approved | 85 |
| perampanel | Eisai | Approved | 85 |
| E2007 + Placebo | Eisai | Phase 2 | 52 |
| Placebo + Rufinamide | Eisai | Phase 3 | 77 |
| E2007 (perampanel) + Placebo | Eisai | Phase 2 | 52 |
| Perampanel Oral Tablet | Eisai | Approved | 85 |
| perampanel | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Zonisamide + Carbamazepine | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Approved | 85 |
| Perampanel and Microgynon-30 + Perampanel and Microgynon-30 | Eisai | Phase 1 | 33 |
| Perampanel | Eisai | Phase 2 | 52 |
| Zonisamide + Placebo | Eisai | Phase 3 | 77 |
| zonisamide low dose group + zonisamide high dose group | Eisai | Approved | 85 |
| E2007 + E2007 + Placebo | Eisai | Phase 2 | 52 |